

3-1-2018

Low- and middle-income countries can reduce risks of subsequent neoplasms by referring pediatric craniospinal cases to centralized proton treatment centers

Phillip J. Taddei
American University of Beirut Medical Center

Nabil Khater
Hôtel-Dieu de France Hospital

Bassem Youssef
American University of Beirut Medical Center

Rebecca M. Howell
University of Texas Health Science Center at Houston

Wassim Jalbout
American University of Beirut Medical Center

See next page for additional authors

Follow this and additional works at: https://repository.lsu.edu/physics_astronomy_pubs

Recommended Citation

Taddei, P., Khater, N., Youssef, B., Howell, R., Jalbout, W., Zhang, R., Geara, F., Giebeler, A., Mahajan, A., Mirkovic, D., & Newhauser, W. (2018). Low- and middle-income countries can reduce risks of subsequent neoplasms by referring pediatric craniospinal cases to centralized proton treatment centers. *Biomedical Physics and Engineering Express*, 4 (2) <https://doi.org/10.1088/2057-1976/aaa1ce>

This Article is brought to you for free and open access by the Department of Physics & Astronomy at LSU Scholarly Repository. It has been accepted for inclusion in Faculty Publications by an authorized administrator of LSU Scholarly Repository. For more information, please contact ir@lsu.edu.

Authors

Phillip J. Taddei, Nabil Khater, Bassem Youssef, Rebecca M. Howell, Wassim Jalbout, Rui Zhang, Fady B. Geara, Annelise Giebeler, Anita Mahajan, Dragan Mirkovic, and Wayne D. Newhauser



Published in final edited form as:

Biomed Phys Eng Express. 2018 ; 4(2): . doi:10.1088/2057-1976/aaa1ce.

Low- and middle-income countries can reduce risks of subsequent neoplasms by referring pediatric craniospinal cases to centralized proton treatment centers

Phillip J Taddei^{1,2,3,*}, Nabil Khater⁴, Bassem Youssef¹, Rebecca M Howell², Wassim Jalbout¹, Rui Zhang^{5,6}, Fady B. Geara¹, Annelise Giebeler², Anita Mahajan², Dragan Mirkovic², and Wayne D Newhauser^{5,6}

¹Department of Radiation Oncology, Faculty of Medicine, American University of Beirut Medical Center, P.O. Box 11-0236, Riad El-Solh, Beirut, 1107 2020, Lebanon

²Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA

³Department of Radiation Oncology, University of Washington School of Medicine, Seattle, WA, 98195, USA

⁴Department of Radiation Oncology, Hôtel-Dieu de France Hospital, University of St. Joseph, P.O. Box 166830, Alfred Naccache Blvd, Beirut, Lebanon

⁵Medical Physics Program, Department of Physics and Astronomy, Louisiana State University, Baton Rouge, LA, 70803, USA

⁶Department of Physics, Mary Bird Perkins Cancer Center, Baton Rouge, LA, 70809, USA

Abstract

Few children with cancer in low- and middle-income countries (LMICs) have access to proton therapy. Evidence exists to support replacing photon therapy with proton therapy to reduce the incidence of secondary malignant neoplasms (SMNs) in childhood cancer survivors. The purpose of this study was to estimate the potential reduction in SMN incidence and in SMN mortality for pediatric medulloblastoma patients in LMICs if proton therapy were made available to them. For nine children of ages 2 to 14 years, we calculated the equivalent dose in organs or tissues at risk for radiogenic SMNs from therapeutic and stray radiation for photon craniospinal irradiation (CSI) in a LMIC and proton CSI in a high-income country. We projected the lifetime risks of SMN incidence and SMN mortality for every SMN site with a widely-used model from the literature. We found that the average total lifetime attributable risks of incidence and mortality were very high for both photon CSI (168% and 41%, respectively) and proton CSI (88% and 26%, respectively). SMNs having the highest risk of mortality were lung cancer (16%), non-site-specific solid tumors (16%), colon cancer (5.9%), leukemia (5.4%), and for girls breast cancer (5.0%) after photon CSI and non-site-specific solid tumors (12%), lung cancer (11%), and leukemia (4.8%) after proton CSI. The risks were higher for younger children than for older children and higher for

*Corresponding author: Phillip J. Taddei, Ph.D., Department of Radiation Oncology, University of Washington School of Medicine, 1959 NE Pacific Street, Box 356043, Seattle, Washington, 98195, USA. Tel.: +1-206-306-2835; Fax: +1-206-598-6218; ptaddei@uw.edu.

girls than for boys. The ratios of proton CSI to photon CSI of total risks of SMN incidence and mortality were 0.56 (95% CI, 0.37 to 0.75) and 0.64 (95% CI, 0.45 to 0.82), respectively, averaged over this sample group. In conclusion, proton therapy has the potential to lessen markedly subsequent SMNs and SMN fatalities in survivors of childhood medulloblastoma in LMICs, for example, through regional centralized care. Additional methods should be explored urgently to reduce therapeutic-field doses in organs and tissues at risk for SMN, especially in the lungs, colon, and breast tissues.

Keywords

pediatric medulloblastoma; second malignant neoplasm risk; craniospinal irradiation; proton therapy; low- and middle-income countries

Classification Numbers (PACS)

87.53.-j; 87.53.Bn; 87.53.Kn; 87.55.-x; 87.55.K-; 87.55.N-

1. Introduction

Survivors of childhood cancer are at high risk of late effects as a result of their treatment [1-7] and at elevated risk compared to survivors of adulthood cancers [8]. The most severe late effects are more common in those who received radiotherapy than those who did not [7, 9-12], and increased radiotherapy dose is associated with increased risk [13, 14]. Still, radiotherapy remains as an essential component of treatment for childhood medulloblastoma (MB) [15]. After a recurrence, the second most frequent cause-specific mortality of long-term childhood cancer survivors is a subsequent malignant neoplasm (SMN) [16]. The central nervous system (CNS) is the second most frequent childhood cancer site, and MB is the most common of these. MB is most commonly diagnosed in children younger than age 10 years, with approximately 9300 diagnoses in children each year worldwide, 80% of whom live in low- and middle-income countries[†] (LMICs) [17-19]. For these reasons, investigations into late effects following radiotherapy for pediatric MB and into reducing those effects are of high importance and relevance globally.

After surgery, pediatric MB and primitive-neuroectodermal-tumor (PNET) patients are treated with craniospinal irradiation (CSI) to eliminate sub-clinical disease that may be present in the tumor bed and in the cerebrospinal fluid circulates around the brain and spinal cord, within the cranium and spinal canal. Nearby normal tissues can receive radiation at high levels sufficient to produce radiogenic late effects. Risks of late effects are intensified for younger children because, in general, their organs are closer to the therapeutic fields and their organs are inherently more sensitive to radiation. In addition, the safety margins of spinal fields of young children are expanded laterally and, in proton therapy, anteriorly to avoid sharp gradients across the growing vertebrae, which increases the dose in the bones, lungs, abdomen, and heart. Normal tissues of childhood MB or PNET survivors are at high

[†]Low- and middle-income countries are those so classified by The World Bank, Country and Lending Groups.

risk of SMNs [20-24], cardiovascular toxicity [25, 26], hearing loss [27-29], neurocognitive impairment [27, 30-34], premature ovarian insufficiency [35-38], chest wall deformities [39], bone growth abnormalities [30, 36], and endocrine dysfunction [40-43]. In the 14,054-participant Childhood Cancer Survivor Study (CCSS) cohort, for example, investigators found a cumulative incidence (CI) of a subsequent neoplasm of 14.6% among MB and PNET survivors at 30 years after their radiotherapy [44]. Thus, children diagnosed with MB, in general, have a high probability of long-term survival [17, 45], but they face escalated risks of radiotherapy-induced SMN compared to the general population.

Because of the challenge of decades-long latency times of most radiogenic cancers [20], no randomized controlled trial or observational study has been reported in the literature with sufficient follow-up time and sample size that compares SMN incidences between photon CSI and proton CSI [46]. However, a few computational studies have projected the lifetime risks of radiogenic late effects in childhood MB survivors based on detailed whole-body dosimetry and dose-effect models, including contributions from secondary particles. These studies have found that delivering proton CSI rather than photon CSI reduces the projected risks of late effects, including ovarian failure [47], cardiac toxicity [48], and various SMNs [49-54]. Only three of these SMN studies, however, accounted for all SMNs from primary and secondary radiation—one (Ref. [50]) was for a single patient in a high-income country (HIC) institution; one (Ref. [51]) was for a cohort of pediatric patients in a HIC institution but did not single out the specific risks of non-melanoma skin cancer (NMSC), leukemia, uterine cancer, and ovarian cancer; and one was for a single patient receiving proton CSI available in a HIC rather than photon CSI in a LMIC. Although most LMICs have the capability to apply three-dimensional conformal radiotherapy (3DCRT) [55], with the recent exception of China, none currently have the ability to deliver proton therapy [56]. Thus, to fill these gaps, it was necessary to conduct a study with heightened site specificity that compared the absolute risks of each known radiogenic SMNs between photon CSI in a LMIC and proton CSI in a HIC for a sample of pediatric MB patients spanning all ages and including both sexes.

The purpose of this study was to estimate exhaustively the reductions in projected lifetime SMN incidence and mortality for children in LMICs if they were treated with proton CSI rather than photon CSI. Specifically, for these children, we compared the SMN risks due to modern standard-of-care 3DCRT treatment plans in a LMIC institution (photon CSI) *versus* those in a HIC institution (proton CSI). Nine patients of ages 2 to 14 years were randomly selected for this *in-silico* virtual clinical trial, including five girls and four boys. For each patient and for each treatment modality, we retrospectively calculated the equivalent dose in each organ or tissue at risk for an SMN, T , and projected the risks of SMN incidence and mortality for the cancer site associated with T , taking into account all known radiogenic SMNs.

2. Methods and Materials

2.1. Patient cohort

A subset of de-identified patient data [57, 58] of nine children—five girls and four boys—who were diagnosed with MB at The University of Texas MD Anderson Cancer Center (MD

Anderson) were collected for this study. Separate CSI plans were created according to the standards of care of two leading cancer care facilities in their regions—the American University of Beirut Medical Center (AUBMC) using photon CSI and MD Anderson using proton CSI [59]. AUBMC is an academic hospital in a LMIC that delivers CSI with 3DCRT, and MD Anderson is an academic cancer hospital in a HIC that is capable of delivering proton therapy [60]. Patient data for this study were selected retrospectively using the systematic random sampling method [61], with the following inclusion criteria: between 2 and 14 years of age diagnosed with MB, treated on protocols or according to the current standards of care, availability of CT image data, and having treatment plans that were created between the dates of 1 August 2006 and 31 May 2010. The study was conducted under protocols approved by the Institutional Review Boards of AUBMC and MD Anderson. The cohort's age distribution was approximately uniformly distributed, ensuring a representative range of body sizes and probabilities of second cancers. The patients' characteristics are listed in table 1.

2.2. Patient images, organ delineation, and file transfer

Simulation computed tomography (CT) images had been acquired as part of the routine proton therapy care for each patient and were collected from archived data. The CT image sets extended from the tops of the patients' heads to their mid-thighs, encompassing the majority of the patients' anatomy. Because the patients were from MD Anderson, unlike MB patients at AUBMC, they were simulated in the supine position and a digital couch was added to the images. For each patient, archived target and avoidance volumes were supplemented to include the contours for the 'whole body' (i.e., that captured in the CT image set) and each T , including, bladder, breast tissue, colon (including rectum), liver, lungs, ovaries, skin, stomach, thyroid, uterus, red bone marrow (RBM), and a 'remainder' volume that was created as a Boolean subtraction between the whole body and the union of all specific SMN-sites. Because magnetic resonance imaging data were insufficient or missing, delineating the ovaries and RBM accurately was difficult. The size and position of the ovaries in the girls were approximated as 0.5-cm-diameter spheres located laterally to the body of the uterus. Bones were segmented within the body by identifying a range of Hounsfield Units between 150 and 3000, and the RBM volume was created automatically as a three-dimensional symmetric inner margin of 0.2-cm in the bones, excluding the teeth, with minor manual post-processing performed (e.g., small cavities filled and small volumes removed). The contours of the ovaries and RBM were confirmed by comparing the former's positions to those of the nominal locations identified by Pérez-Andújar *et al* [47] and the latter's regional anatomical percentages to those of the mathematical-model-based proportions of children derived by Cristy [62]. These images and contours were exported to RT Image and RT Structure Set objects in the Digital Imaging and Communications in Medicine-Radiation Therapy (DICOM-RT) format, which were de-identified to preserve anonymity of the patients and sent to AUBMC via password-protected and encrypted file transfer.

2.3. Treatment planning

Treatment planning methods followed those of previous studies [52, 57, 63] and are briefly reviewed here. CSI fields were consistent with those of routine clinical practice of each

institution—photon CSI at AUBMC and proton CSI at MD Anderson. Each CSI plan comprised left and right lateral or slightly posterior oblique cranial fields and one to three adjacent posterior-anterior spinal fields, depending on the length of spine. The photon and proton treatment plans had a common intent, specifically, to sterilize potential residual cancer cells in the clinical target, i.e., the tumor bed, cranial cavity, and spinal canal.

Photon CSIs were planned and therapeutic doses were calculated using a commercial treatment planning system (Panther, version 4.72, Prowess Inc., Concord, CA, USA). Fields of 6-Megavolt energy were designed to deliver a prescribed dose, D_{Rx} , of 23.4 Gy in 1.8-Gy fractions in the clinical target. Although normally junctions of abutting fields would be shifted longitudinally twice during the course of treatment and sub-fields would be added to improve the distribution of dose, for this study, these shifts and sub-fields were disregarded.

Proton CSIs were planned and therapeutic doses were calculated using a commercial treatment planning system (Eclipse, version 8.9, Varian Medical Systems, Inc., Palo Alto, CA, USA). Passive-scattering spread-out proton beams of nominal energies (i.e., energies prior to range shifting and modulation) between 140 MeV and 225 MeV were designed to deliver a D_{Rx} of 23.4 Gy-RBE in 1.8 Gy-RBE fractions in the clinical target of each field. Following the recommendation of the International Commission on Radiation Units and Measurements [64], we applied an RBE value of 1.1 for protons, such that the D_{Rx} corresponded to an absorbed dose of 21.3 Gy.

Boost doses directed to the tumor resection bed were omitted in this research study because they bear much less importance for SMN risk than CSI fields [65]. All treatment plans were reviewed and approved by a board-certified radiation oncologist of the corresponding clinic (AM or FG).

2.4. Mean equivalent dose in each organ and tissue

For each patient, the mean equivalent dose, H_T , in each organ or tissue, T , was calculated as the mass-weighted mean of the equivalent dose in Sv, H_v , in each voxel, v , averaged over all v in T , or

$$H_T = \frac{\sum_{v \text{ in } T} H_v m_v}{\sum_{v \text{ in } T} m_v}, \quad (1)$$

where m_v was the mass of the tissue in v , where

$$H_v = \bar{w}_R \cdot D_v, \quad (2)$$

and where \bar{w}_R was the mean radiation weighting factor and D_v was the absorbed dose in Gy in v . H_T , H_v , and D_v were estimated separately for therapeutic and stray radiations. For organs and tissues that were not captured completely in the CT image sets, i.e., RBM, skin,

remainder, and whole body volumes, H_T values were reduced by the ratio of the mass of the captured portion of the patient to the mass of the patient recorded at treatment in his or her medical record. These values are listed in table 1.

Values of D_v from therapeutic radiation were calculated for each v throughout the modeled geometry of each patient using the TPS of each institution, with an isotropic dose calculation grid of 0.25 cm. The \bar{w}_R value for all photons beams was taken as 1, and the \bar{w}_R value of therapeutic protons was estimated as the approximate mean quality factor of 1.1 at any point within the fields based on linear-energy-transfer, microdosimetric, and radiobiological studies [66-72]. We applied \bar{w}_R values from similar fields of previous studies, which found small variations between patients for neutrons produced inside the patients' bodies ('internal neutrons') and neutrons produced in the treatment unit ('external neutrons'). Specifically, the \bar{w}_R values were 7.8 for external neutrons from cranial fields, 8.1 for external neutrons from spinal fields and, and 9.0 for internal neutrons [50, 65].

Stray radiation dose was estimated in the following manner. In photon CSI, because out-of-field dose has been shown to be inaccurately calculated by TPSs [73-75], the in-field H_v values were kept and the out-of-field H_v values were replaced. In particular, a measurement-based model for out-of-field dose as a function of distance to the field edge derived in a previous study [75] was used to replace the H_v values that were at least 1 cm away from the 50% isodose surface. Specifically, the following equation was applied to determine H_v in Sv:

$$H_v = \bar{w}_R \cdot D_{Rx} \cdot \frac{1 \text{ Gy}}{100 \text{ cGy}} \cdot \left[\frac{\alpha_1}{\sqrt{2\pi\sigma_1^2}} e^{-\frac{(r-\mu_1)^2}{2\sigma_1^2}} + \frac{\alpha_2}{\sqrt{2\pi\sigma_2^2}} e^{-\frac{(r-\mu_2)^2}{2\sigma_2^2}} \right], \quad (3)$$

where $\alpha_1 = 224.8 \text{ cm-cGy/Gy}$, $\mu_1 = -2.16 \text{ cm}$, $\sigma_1 = 1.57 \text{ cm}$, $\alpha_2 = 224.3 \text{ cm-cGy/Gy}$, $\mu_2 = -7.43 \text{ cm}$, and $\sigma_2 = 10.28 \text{ cm}$. In-house codes were used to replace the out-of-field H_v values in the DICOM-RT files. In proton CSI, stray neutron contributions to H_v were considered separately from the TPS because of the increased RBE for carcinogenesis of neutrons compared to protons. Because neutron doses are not calculated separately by the TPS, the Monte Carlo Proton Radiotherapy Treatment Planning (MCP RTP) system was used to calculate contributions to H_v from neutrons, and these values were added to contributions to H_v from protons. Data were extracted from each patient's DICOM-RT files to produce input files to its dose engine (Monte Carlo N-Particle eXtended code, version 2.7c, Los Alamos National Laboratory, Los Alamos, NM, USA) for simulating particle tracking and dosimetry through a field-specific proton source definition and geometry of the passive-scattering treatment unit (Probeat, Hitachi America, Ltd., Brisbane, CA, USA) and CT-based voxelized anatomy of the patient. A lattice tally [76] determined D_v per source particle throughout the patient anatomy from therapeutic protons, internal neutrons, and external neutrons. For every patient and particle type, D_v per source particle value was, first, scaled by the planned percentage weight of each field and, second, divided by the mean therapeutic proton D_v per

source particle averaged in a central normalization sub-volume of the clinical target. This resulted in D_v in terms of Gy per therapeutic proton Gy for every patient and particle type.

Uncertainties were propagated for voxel and organ doses. For proton CSI, the Monte Carlo simulations conferred less than 0.3% and less than 4% statistical uncertainty in H_T from therapeutic protons and secondary neutrons, respectively. For photon CSI, uncertainties of less than 5% were applied for in-field H_v and the analytical model's root mean square deviation of 0.0167 Sv/Gy was applied for out-of-field H_v .

2.5. Radiogenic SMN risk for each cancer site

The lifetime attributable risk, LAR , of SMN incidence, $LAR_{I,T}$, for each radiogenic solid-tumor site that corresponded to T was determined using a linear-no-threshold model,

$$LAR_{I,T} = \frac{I_T}{H_{\text{ref}}} \cdot H_T, \quad (4)$$

in which I_T values were risk coefficients interpolated linearly between ages that were listed for $H_{\text{ref}} = 0.1$ Sv for each sex and SMN site in Table 12D-1 of the BEIR VII Report of the National Research Council of the National Academies (NRCNA) [77]. $H_{\text{remainder}}$ was used to estimate the risk of solid cancers that may be located outside of the listed specific cancer sites, or 'other solid' tumors. Because incidence risk coefficients for NMSC were not provided in the BEIR VII Report, we instead applied values of I_{NMSC} that were derived from ICRP Publication 60 [68], adjusting for age and sex, as described previously [65].

Unlike solid tumors, because the NRCNA recommended a no-threshold linear-quadratic model of risk as a function of dose for $LAR_{I,\text{leukemia}}$, it was necessary to give the projected risks of leukemia special consideration. For low to moderate doses, this could be done by applying the recommended quadratic rather than linear multiplicative term, $D + \theta D^2$, where θ was related to the degree of curvature of the function. However, this model was based on the data of Preston *et al* [78], who fit a linear-quadratic model to updated dosimetric data in the range of 0 to 2 Gy. Their data was for atomic bomb survivors, and the recommended model did not account for cell sterilization, post-therapy repopulation, and circulation effects that may occur from fractionated exposures in a childhood radiotherapy cohort [79, 80]. Notwithstanding this omission, excess relative and absolute risk estimates of leukemia derived from medical radiation studies, with average doses ranging up to 2 Gy, were similar to those of the model [77 pp. 13, 183, 188]. However, in the case of CSI of young children, the mean equivalent dose in the red bone marrow can exceed 2 Sv and are neither acute nor chronic. For these reasons, we were motivated to not overestimate the $LAR_{I,\text{leukemia}}$ for children in the same way as Berrington de Gonzelez *et al*, who cited the "limited information about the shape of the dose response curve above about 2 Gy," and lack of statistical power at high doses [81]. They reserved the linear-quadratic model for acute doses only, applied a linear model for chronic exposures, and restricted the application of their algorithm to "lower than about 1 Gy" for childhood exposures. Similarly, we applied the full linear-quadratic model to 2 Sv and removed the quadratic term above 2 Sv. In other words,

$$LAR_{I, leukemia} = \begin{cases} I_{leukemia} \left(\frac{H_{RBM} + \theta H_{RBM}^2}{H_{ref} + \theta H_{ref}^2} \right), & \text{for } H_{RBM} \leq 2 \text{ Sv} \\ I_{leukemia} \left[\frac{(2 \text{ Sv}) + \theta (2 \text{ Sv})^2}{H_{ref} + \theta H_{ref}^2} \right] + I_{leukemia} \left(\frac{H_{RBM} - 2 \text{ Sv}}{H_{ref}} \right), & \text{for } H_{RBM} > 2 \text{ Sv} \end{cases}, \quad (5)$$

where θ was 0.88 Sv^{-1} . By combining like terms and inserting the values for θ and H_{ref} , equation 2 was simplified to the following:

$$LAR_{I, leukemia} = \begin{cases} I_{leukemia} \left(\frac{H_{RBM} + \theta H_{RBM}^2}{H_{ref} + \theta H_{ref}^2} \right), & \text{for } H_{RBM} \leq 2 \text{ Sv} \\ I_{leukemia} \left[50.7 + \frac{H_{RBM} - 2 \text{ Sv}}{H_{ref}} \right], & \text{for } H_{RBM} > 2 \text{ Sv} \end{cases}. \quad (6)$$

As an example, this $LAR_{I, leukemia}$ model is shown in figure 1 for a 5-year-old boy and a 5-year-old girl. Compared to applying the linear-quadratic model directly, this approach was intended to result in lower $LAR_{I, leukemia}$ values at high H_{RBM} , than if we applied the recommended linear-quadratic model directly.

The BEIR VII Report and ICRP Publication 60 contained recommendations for dose- and dose-rate effectiveness factors (DDREFs) to be applied to reduce the risk estimates of solid tumors for low-dose and low-dose-rate exposures. For solid tumors in which the exposures are of high dose but the dose rates are moderate or fractionated, DDREFs should be applied as 1.5 for all solid tumors except NMSC and 2.0 for NMSC. For leukemia, the rationale for DDREF had already been accounted in the curvature of the linear-quadratic portion of the BEIR VII model, so we did not correct additionally our risk values for leukemia.

The above methods were used in the same way to project the LAR of mortality for each cancer site, $LAR_{M, T}$, except substituting M_T for I_T , in which the values of M_T were risk coefficients interpolated between ages listed for each sex and SMN site in Table 12D-2 of the BEIR VII Report. Because mortality risk coefficients were not provided in the BEIR VII Report for thyroid cancer and NMSC, for $M_{thyroid}$ and M_{NMSC} we multiplied the values of $I_{thyroid}$ and I_{NMSC} , respectively, by the proposed lethality fractions for thyroid cancer (0.1) and NMSC (0.002), respectively, taken from ICRP Publication 60. Values of I_T and M_T derived for each patient are listed in table 1.

We did not consider a possible leveling (i.e., plateau) of the slope in the dose-effect model at high doses. This decision was based on the very limited evidence of this effect in cancer survivors, especially when considering individual SMN sites [46]. The exceptions of this are

breast cancer, which may (or may not) plateau at high doses, and thyroid cancer, which appears to downturn at doses beyond those of this study [82, 83].

2.6. Total lifetime risk of any SMN

We calculated total lifetime risks of SMN incidence and mortality in the following manner. The total LAR of developing any cancer, $LAR_{I,\text{total}}$, was the sum of the LAR values for each cancer site, or

$$LAR_{I,\text{total}} = \sum_T LAR_{I,T}. \quad (7)$$

We assumed that the risk for development of a radiogenic cancer was independent of developing any other radiogenic cancers and that it is possible to develop multiple SMNs [2]. In other words, because of the mathematical possibility of attributing an incidence to multiple cancers, the sum was used and correlated terms were not subtracted. However, because of the mathematical impossibility of attributing a fatality due to multiple cancers, we calculated the total LAR of any fatal cancer, $LAR_{M,\text{total}}$, differently than $LAR_{I,\text{total}}$. Specifically, unlike the NRCNA, who calculated $LAR_{M,\text{total}}$ as the sum of each $LAR_{M,T}$, we considered fatal cancers to be mutually exclusive events in the model, i.e., a person cannot die of one radiogenic cancer and then subsequently die of other radiogenic cancers. In this case, the correlated terms— $LAR_{M,\text{bladder}} \times LAR_{M,\text{breast}}$, $LAR_{M,\text{bladder}} \times LAR_{M,\text{breast}} \times LAR_{M,\text{colon}}$, and so on—would need to be omitted. However, rather than taking the sum of all $LAR_{M,T}$ and then subtracting all correlated terms, to account for this, we used the following methods to achieve the equivalent result. The probability of surviving of any single radiogenic cancer, S_T , was defined as the complement of $LAR_{M,T}$, so that S_T was one minus $LAR_{M,T}$. Similarly, the probability of surviving all SMNs, S_{total} , was one minus $LAR_{M,\text{total}}$. Assuming that each S_T was independent of surviving all other cancers, S_{total} was the product of the probabilities of surviving each SMN. As a result, the following was true:

$$LAR_{M,\text{total}} = 1 - S_{\text{total}} = 1 - \prod_T S_T = 1 - \prod_T (1 - LAR_{M,T}). \quad (8)$$

In summary, like the NRCNA, we used equation 7 to determine $LAR_{I,\text{total}}$, and, unlike the NRCNA, we used equation 8 to determine $LAR_{M,\text{total}}$.

2.7. Ratio of SMN risk

When comparing two treatment modalities in terms of SMN risk, it has been shown that the ratios of LAR carry less uncertainty than absolute LAR values [84-87]. Therefore, as a relative figure of merit, we defined the ratio of the LAR from proton CSI to the LAR from photon CSI, $RLAR$, or

$$RLAR = \frac{LAR(\text{proton CSI})}{LAR(\text{photon CSI})}. \quad (9)$$

In both incidence and mortality, the risk coefficients of each cancer site cancel each other in the numerator and the denominator of $RLAR$, resulting in identical values for $RLAR_{f,T}$ and $RLAR_{M,T}$. Therefore, we reported $RLAR_T$ values, which were applicable to incidence and mortality. However, the same was not true for $RLAR_{I,total}$ and $RLAR_{M,total}$, so these ratios were calculated separately for incidence and mortality. We reported mean $RLAR$ values averaged across all patients for each T , $RLAR_T$, any T for incidence, $RLAR_{I,total}$, and any T for mortality, $RLAR_{M,total}$. Unlike dose values, variances in these mean $RLAR$ values were reported at approximately the 95% confidence level (i.e., as two sample standard deviations). One-sided t-tests ($\alpha = 0.05$) were performed separately to determine whether $RLAR_{I,total}$ and $RLAR_{M,total}$ were significantly less than 1 ($H_0: RLAR = 1, <1$), which would indicate that proton CSI confers less LAR than photon CSI with significance.

3. Results

3.1. Mean equivalent dose in each organ and tissue

Values of H_T are listed in table 2 for photon CSI at AUBMC and proton CSI at MD Anderson for the five girls and four boys in this study. Most H_T values followed a general trend of being larger for younger children than for older children, indicating H_T is strongly affected by the size of the patient. The most notable exception to this was H_{liver} in proton CSI, which had the opposite trend of larger values for older patients. For H_{RBM} and $H_{prostate}$ in photon CSI and H_{RBM} , $H_{breasts}$, H_{liver} , $H_{ovaries}$, and H_{uterus} in proton CSI, we did not observe a dependency on age. For each patient, in photon CSI, the H_T values were greater than 1 Sv in all T , except for the prostate. However, in proton CSI, only H_{RBM} , $H_{remainder}$, H_{skin} , and H_{lungs} were greater than 1 Sv. In some cases, high H_T values indicated that the photon CSI therapeutic fields crossed organs at risk that are not usually considered to be within the CSI target, for example, the bladder of the 3-year-old boy. The overall statistical uncertainties in H_T ranged from less than 1% for most T to less than 10% for small organs and tissues (i.e., prostate, uterus, and ovaries).

In general, even after accounting for stray radiation, mean H_T values were higher for photon CSI than for proton CSI. These values and their 95% confidence intervals are listed in table 2. The average H_T was higher for photon CSI than for proton CSI for all T , except the skin, which had approximately equal H_T . Only a slight reduction in average H_T for proton CSI was observed for the lungs, remainder, and RBM. The variances in H_T were due to the trends in H_T with age as well as the degree of partial irradiation of some organs and tissues, not because of statistical uncertainties. Apart from the whole body volume, the organs and tissues that received the highest average H_T values in photon CSI were the thyroid, RBM, colon, and remainder, and those for proton CSI were the RBM, remainder, skin, and lung.

In proton CSI, neutrons accounted for large portions of H_T for several organs and tissues. Contributions to H_T from external and internal neutrons along with average values are listed for each patient in table 3. Neutrons accounted for more than 40% of the average H_T in the prostate, breast tissue, ovaries, uterus, bladder, thyroid, stomach, liver, and colon. In these organs and tissues, more than two-thirds of the neutron equivalent doses were from external

neutrons, except for the thyroid, in which there was an even contribution between external and internal neutrons.

3.2. Radiogenic SMN risks for each cancer site

The average projected $LAR_{I,T}$ values (figure 2a) were higher in photon CSI than in proton CSI for every radiogenic cancer category, with the exception of NMSC, and these risks varied greatly between cancer sites. Average projected lifetime risks of incidence greater than 10% were found in other solid tumors, NMSC, lung cancer, and leukemia in both photon and proton CSI and in thyroid cancer, breast cancer, and colon cancer in photon CSI. Average projected absolute reductions in risk of incidence by more than 11% by applying proton CSI rather than photon CSI were observed in thyroid cancer, breast cancer, and colon cancer. Compared to boys, girls were at more than twice the lifetime risk for thyroid cancer, lung cancer, and NMSC in both modalities and stomach cancer in photon CSI. Compared to girls, boys were at elevated lifetime risk of developing a liver cancer and bladder cancer in both modalities and colon cancer in proton CSI. Children of ages at exposure less than 8 years had higher lifetime risk of incidence than children of ages at exposure greater than 8 years in every cancer site for both modalities, and this was true by more than a factor of 2 for bladder cancer and other solid tumors in both modalities, prostate cancer in proton CSI, and breast cancer and lung cancer in photon CSI.

The average projected $LAR_{M,T}$ values (figure 2b) were higher in photon CSI than in proton CSI for every radiogenic cancer site having non-negligible $LAR_{M,T}$, and these risks varied greatly between cancer sites. The highest average lifetime risks of mortality (i.e., greater than 4%) were for lung cancer, other solid tumors, and leukemia in both modalities and for colon cancer and breast cancer in photon CSI. Average projected reductions in risk of mortality by more than 4% by applying proton CSI rather than photon CSI were observed in colon cancer, lung cancer, and breast cancer in girls. Compared to boys, girls were at more than twice the lifetime risk of a fatal thyroid or lung cancer for both modalities and a fatal stomach cancer for photon CSI. In these T , they also had much larger risk coefficients than boys. Compared to girls, boys were at almost twice the lifetime risk of developing a fatal colon cancer in photon CSI. With the exception of leukemia, children of ages at exposure less than 8 years had higher lifetime risk of mortality than children of ages at exposure greater than 8 years for every cancer site and both modalities, and this was true by more than a factor of 2 for bladder cancer and other solid tumors in both modalities, prostate cancer in proton CSI, and breast cancer and lung cancer in photon CSI. Unlike with incidence, we did not observe a relationship between the lifetime risk of a fatal leukemia and age at exposure in photon CSI or proton CSI.

3.3. Total lifetime risks of any SMN

For each treatment, total risks of any SMN incidence and SMN fatality were computed as $LAR_{I,total}$ and $LAR_{M,total}$, respectively, while excluding the unrealistic risk of a fatality from multiple cancer sites (see section 2.4). The variations in the average values below were reported as two sample standard deviations of each mean value and, therefore, reflect variability across ages rather than the small uncertainties in physical dose calculations or large uncertainties in the risk model.

The mean $LAR_{I,total}$ values averaged across patients of all ages and both sexes were $168\% \pm 111\%$ and $88\% \pm 44\%$ for photon CSI and proton CSI, respectively. The girls were at higher risk of any SMN incidence than the boys by factors of 1.98 ± 1.53 and 1.47 ± 1.07 for photon CSI and proton CSI, respectively. Children less than 8 years of age at exposure were at approximately twice the $LAR_{I,total}$ than children greater than 8 years of age for either treatment modality. NMSC accounted for approximately one-sixth and one-third of $LAR_{I,total}$ of each patient for photon CSI and proton CSI, respectively. In proton CSI, the contributions to $LAR_{I,total}$ from external neutrons and internal neutrons were small compared to those of therapeutic protons, specifically, they were $5.0\% \pm 2.1\%$ and $3.6\% \pm 1.7\%$, respectively, or, together, one-tenth of the overall risk.

The mean $LAR_{M,total}$ values averaged across patients of all ages and both sexes were $41\% \pm 18\%$ and $26\% \pm 10\%$ for photon CSI and proton CSI, respectively. The girls were at higher risk of any fatal SMN than the boys by factors of 1.43 ± 0.78 and 1.34 ± 0.77 for photon CSI and proton CSI, respectively. Children less than 8 years of age at exposure about 1.6 times higher $LAR_{M,total}$ than children greater than 8 years of age at exposure for either treatment modality. In proton CSI, the contributions to $LAR_{M,total}$ from external neutrons and internal neutrons were small compared to those of primary protons, specifically, they were $1.8\% \pm 0.6\%$ and $1.1\% \pm 0.4\%$, respectively, or, together, one-ninth of the overall risk.

3.4. Ratios of SMN risks

The values of $RLAR_T$ for the nine patients are shown in figure 3 for each T . The $RLAR_T$ values were much less than 1 for subsequent bladder, breast, liver, ovarian, prostate, stomach, thyroid, uterine, and colon cancers and less than 1 for other solid tumors, leukemia, and lung cancer. Among these, the statistical significance of $RLAR_T < 1$ was weakest for subsequent lung cancer, having a p -value of 0.012 for its one-sided t-test. In two cases, the 6- and 9-year-old girls, $RLAR_{lung}$ was not less than 1. $RLAR_{NMSC}$ was greater than 1 for each patient except the 9-year-old boy, which suggests that proton CSI is of no benefit over photon CSI for reducing the risk of NMSC. The only cancer site in which a relationship was observed clearly between $RLAR_T$ and age was breast cancer, for which the $RLAR_T$ values increased with age, indicating that a larger reduction in breast cancer risk by proton CSI may be achieved for younger girls than for older girls.

Values of $RLAR_{I,total}^-$ and $RLAR_{M,total}^-$ for the cohort were 0.56 (95% CI, 0.37 to 0.75) and 0.64 (95% CI, 0.45 to 0.82), respectively. This result indicated with statistical significance the potential of reducing the risk of SMN in future pediatric MB patients in LMICs by replacing photon CSI with proton CSI. Specifically, the projected lifetime risks of SMN incidence and mortality were reduced by 44% and 36%, respectively. The value of $RLAR_{I,total}^-$ was slightly lower for girls than for boys, but $RLAR_{M,total}^-$ values were similar between girls and boys. This could be interpreted as a slightly stronger potential reduction in SMN incidence for girls compared to boys by using proton CSI rather than photon CSI. Similar values of $RLAR_{I,total}^-$ and $RLAR_{M,total}^-$ were observed in younger children and in older children.

4. Discussion

In this inter-institutional, international *in-silico* clinical trial, we tested for the potential reduction in lifetime SMN risk if children with medulloblastoma in LMIC were to be treated with proton CSI instead of photon CSI. We found that the projected lifetime risks of SMN incidence and mortality were reduced by 44% and 36%, respectively, by proton CSI. The risks of SMN incidence were especially reduced for thyroid, breast, and colon cancer and were not reduced for NMSC. The largest differences in the lifetime risk of a fatal SMN were found for colon, lung, breast, thyroid, and other solid tumors. For most specific SMN sites, the average lifetime risks of SMN incidence or mortality were reduced by more than a factor of 6 by proton CSI. We found that, in general, girls were at higher risk than boys, younger patients were at higher risk than older patients, and proton CSI reduced the SMN risk for girls more than it did for boys.

Lung cancer was identified as the specific cancer site both of the greatest concern and having the greatest opportunity for preventing a fatal SMN by replacing photon CSI with proton CSI. This was especially true for girls. Among site-specific SMNs, lung cancer accounted for more than half the mortality risk. The potential difference in risk of a lung cancer fatality between photon CSI and proton CSI was 5.4%. For these reasons, this study has identified the lungs as an organ at risk needing urgent attention in the treatment of childhood medulloblastoma to reduce the radiation dose and subsequent risk of SMN. Another concerning cancer site for girls, especially young girls, was breast cancer, with a difference of 4.6% in the risk of a fatality between photon CSI and proton CSI. Minimizing the lateral margins of the spinal fields but ensuring excellent set up would reduce exit dose through the lungs, and breast tissue in girls, without compromising on the dose in the clinical target.

Our finding of the reduced LAR_I and LAR_M for proton CSI *versus* photon CSI was consistent with those of other predictive risk studies in the literature. However, the reductions were weaker in this study compared to previous studies [49, 51, 88]. For example, the values of $RLAR_{I, total}^-$ and $RLAR_{M, total}^-$ in this inter-institutional study (0.56 ± 0.19 and 0.64 ± 0.19 , respectively) were at least twice those of a previous intra-institutional study (0.15 ± 0.04 and 0.32 ± 0.09 , respectively) [51]. One reason for the difference in results between the two studies was that our study accounted for all known SMN sites while the previous study combined subsequent leukemia, uterine cancer, ovarian cancer, and NMSC into the other solid tumors category. If leukemia, uterine cancer, ovarian cancer, and NMSC were removed, our $RLAR_{I, total}^-$ and $RLAR_{M, total}^-$ values (0.40 ± 0.20 and 0.59 ± 0.22 , respectively) would shift closer to those of the previous study. Another difference between the studies that may affect the ratios of risks was the lower average age in the sample set in this study (8 years) compared to that of the previous study (9 years). The remaining differences in risks between the two studies reveal that SMN risks may differ between institutions, in particular, for photon CSI. An independent study by Stokkevåg *et al* [88] applied the same risk model as our study to compare second cancer risks between CSI modalities for 6 children of ages 5 to 11 years. They reported mean $LAR_{I, total}$ values of 78% and 11% for photon CSI and passive-scattering proton CSI, respectively. However, they

considered only subsequent bladder, liver, stomach, colon, lung, and thyroid cancer. If we neglected breast cancer, ovarian cancer, prostate cancer, other solid tumors, NMSC, uterine cancer, and leukemia, then our mean $LAR_{I,total}$ values aligned well with theirs, at $78\% \pm 56\%$ and $15\% \pm 8\%$ for photon CSI and proton CSI, respectively.

Our results may be compared roughly to those of epidemiological studies of childhood MB survivors. However, with the exceptions of subsequent leukemias, gliomas, or meningiomas that may occur within a few years of radiotherapy [21, 89-92], lifelong follow-up is needed to fully appreciate the CIs of most SMNs because of their extended latency periods [20]. As long-term follow-up data for proton CSI is particularly absent in the literature, we restricted our comparison to photon CSI. At 30 years after exposure, the North American CCSS found CIs of 11% SMN and 4.1% NMSC in MB or PNET survivors who received radiotherapy [44]. The following non-CSI-specific studies are useful in approximating how these CIs will multiply with lifetime follow-up. Between 30 and 40 years after childhood exposure, a French and British study [93] found the CI of radiotherapy-induced kidney cancer to triple. Beyond 45 years after exposure, the CI continued to steadily increase. Between ages 40 and 55 years, the CCSS [94] found CIs of new SMN of 18% and new NMSC of 20%. From ages 60 and 80 years, a Nordic study of pre-chemotherapy childhood survivors [95] found that the CI of SMN increased from 18% to 48%, a factor of 2.7. Taking these multiplicative factors into account to extrapolate the CSI-specific data well beyond 30 years of follow-up, our projected average lifetime risks of SMN and NMSC of 142% and 26%, respectively, resembled the epidemiological data. In addition, the sample set in our study was younger than those of the above studies, and we found that younger children receiving CSI were at twice the risk of SMNs than older children. On this basis, our projected lifetime risks may be more reliable for childhood MB survivors than the limited CSI-specific historical data collected to date.

In proton CSI, the contributions to total risks of SMN incidence or mortality from secondary neutrons were small but not negligible. In general, their fractions of risks (approximately one-ninth) aligned well with those of most previous proton CSI studies [50, 52, 65, 96, 97]. Some minor differences may be attributable to the sizes of the bodies of the patients, the choice of w_R values for neutrons, and the application of a risk model, especially for leukemia. This result further strengthened our previous observations that only small, probably clinically-insignificant reductions in risk would be achieved by eliminating external neutrons, e.g., using magnetically-scanned machines [98]. That said, the potential advantages of intensity-modulated proton therapy for reducing the risk by better conformity of the therapeutic proton dose to the target volumes have not been evaluated. We conclude that, although it is clear that investigations into reducing secondary neutron exposures are warranted [99], their influence on total risks of SMN incidence and mortality were small compared to that of therapeutic protons. For this reason, developing methods of reducing exposures of healthy tissues to therapeutic proton fields, e.g., through intensity-modulated proton therapy [100], may be of much greater value than reducing secondary neutron exposures [101].

Based on the results of this study, it is possible to derive an approximate number of fatal SMNs that may be avoided if proton therapy were expanded to children in all developing countries. Approximately 1.64 billion children of ages 14 or less live in developing countries [18, 19] having 8300 annual diagnoses of MB [17, 102]. Applying a 5-year event-free survival probability of 81% [45, 103], among those who are treated, approximately 6700 new long-term survivors of pediatric MB emerge in developing countries per year. Then, using the difference in mean $LAR_{M,total}$ between photon CSI and proton CSI in our study, we find that 1010 subsequent cancer deaths in childhood MB survivors could be prevented annually if proton therapy became available globally. Assuming a conservative 3% annual growth rate [102, 104], 48,000 cancer deaths could be prevented over 30 years. The same methodology can be applied to estimate the benefit of a single installation in a region of developing countries, such as in Lebanon. A centralized proton therapy center in Lebanon would attract patients from the region of the Middle East comprising Lebanon, Syria, Jordan, and Iraq (LSJI). Approximately 24 million children under 14 years of age live in LSJI [60], among whom will be 4000 new cases of cancer each year [17]. Among pediatric cancer patients treated at AUBMC, 11% have CNS cancer, a third of whom are diagnosed with MB [105]. Assuming the same proportion for the regional population, we estimate the number of childhood MBs in LSJI each year as 150, which corresponds to the potential of preventing 870 cancer deaths over 30 years with proton CSI.

Centralized proton therapy may also result in a health-care cost savings. The least expensive proton therapy option on the market today costs approximately \$30 million for a two-gantry solution [106]. A conventional single linear accelerator installation costs conservatively \$3 million [107]. Assuming a life cycle of 30 years for proton therapy and 10 years for a linear accelerator, the added cost of a proton therapy machine for two treatment rooms would be \$12 million over 30 years [108]. To put this amount into perspective, this is approximately one-fortieth of the cost of a single medication (trastuzumab) to treat breast cancer in Lebanon [109] in the same time period. By dedicating half of one gantry to treat pediatric MB using proton CSI rather than photon CSI, the added cost per prevented SMN fatality would be roughly \$3500. The average cost of treating a single cancer in Lebanon is \$7800 per patient [109]. Neglecting travel and other tertiary costs, the above analysis provides a first approximation of the long-term beneficial cost-effectiveness of centralized proton therapy for the 24 million children within reach of Beirut by bus [19].

In general, we found that organ equivalent doses were strongly dependent on the size of the patient. This emphasized the importance of considering a variety of ages when performing dosimetric studies in the pediatric radiotherapy setting and suggested that the contouring of organs at risk for SMNs as a routine clinical practice in CSI should be considered so that these organs can be more deliberately avoided. Similarly to the previous intra-institutional study, we did not find differences in $RLAR_{M,T}$ between younger and older children.

The main limitation of this study is uncertainties in our SMN risk estimation [77, 110], due primarily to the large assumptions in the risk model and not due to the physical absorbed dose. Some of these uncertainties resulted from the following: sampling variability when developing the models, estimating DDREF in a radiotherapy setting, relative biological

effectiveness of the radiation, non-linearities in the relationships between risk and dose, bias in applying risk models and lethality factors based on the Life Span Study cohort to other populations [77], incomplete follow-up of exposed populations on which the models are based, and errors in dosimetry, disease detection, and diagnosis for these populations [110]. Specifically, we applied a model based largely on Japanese children exposed 70 years ago to in an atomic bomb setting and not on U.S. and Arab pediatric radiotherapy follow-up data. Although there is no evidence to reject the extrapolation of linear-no-threshold models to higher doses for solid tumors, it is notable that the data on which the model was based was lacking at high doses such as those experienced in the radiotherapeutic setting. In the case of leukemia, we conservatively adjusted the recommendation from the NRCNA to avoid vastly overestimating the risks at high RBM doses. Second, the DDREF recommended by the NRCNA carried large uncertainties, and a DDREF for daily, fractionated exposures was not provided—its error by applying the model to fractionated rather than acute exposures could be as much as a factor of 2 [77]. That said, a review of the epidemiological literature by Berrington de Gonzalez *et al* [111] revealed that “carcinogenesis from fractionated high-dose exposures [(i.e., more than 5 Gy)] are generally consistent with current theoretical models” that were based mainly on comparatively low-dose (i.e., less than 2 Gy) data. Third, RBEs may differ greatly between the mixed photon-neutron radiation exposures of the atomic bomb survivors and photon or proton-neutron CSI settings, and incorrectly accounting for these three factors may have lead to systematic biases. Ultimately, to reduce these uncertainties, models to predict *LAR* of non-fatal or fatal SMNs in pediatric cancer patients should be derived from large-cohort childhood cancer populations [112]. Because of the large uncertainties in absolute risks, it has been argued that only ratios of risk should be reported when comparing SMNs in clinical or research settings [86]. Others have asserted that only clinical data with decades of follow-up should affect clinical decisions [113, 114]. Although we agree that the ratios of risks are more reliable than absolute risk projections [84, 85, 87], when reporting ratios of risk, it is important to weight the relevance or impact of those values by also making rough estimates of absolute risk. Otherwise, if judging by *RLAR* values alone, one could make incorrect conclusions about the importance of proton CSI in reducing certain SMN fatalities. The improper interpretation of ratios of risk could be solved by also providing either quantitative estimates (i.e., percent) [81] or categorical estimates (i.e., negligible, low, moderate, high, or very high) [26].

In conclusion, we found that the availability of proton therapy to children with MB in LMICs may significantly reduce the total lifetime risk of subsequent malignancies and identified lung cancer as the specific site of highest projected risk of any fatal SMN. Our findings support the expansion of access to proton therapy to pediatric cancer patients in regions in which proton beams are not available, including LMICs, to reduce normal tissue exposures and subsequent radiogenic risks. Such expanded access through regional centers may now be economically feasible. Because the absolute lifetime risks were very high, additional methods of reducing radiation exposures from primary (therapeutic) fields in normal tissues at risk for SMN should be explored as a high priority.

Acknowledgments

The authors are grateful for the assistance of Wendi Koontz-Raisig in contouring organs at risk and Dr. Zeinab Charaf in formalizing the leukemia risk model. This work was supported in part by the Fogarty International Center award K01TW008409, the National Cancer Institute award 1R01CA131463-01A1, and Northern Illinois University through a subcontract of Department of Defense award W81XWH-08-1-0205. The content is solely the responsibility of the authors and does not necessarily represent the official views of the sponsors.

References

- 1 Oeffinger KC, et al. Chronic health conditions in adult survivors of childhood cancer. *N Engl J Med*. 2006; 355:1572–82. [PubMed: 17035650]
- 2 Armstrong GT, et al. Occurrence of multiple subsequent neoplasms in long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. *J Clin Oncol*. 2011; 29:3056–64. [PubMed: 21709189]
- 3 Geenen MM, et al. Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. *JAMA-J Am Med Assoc*. 2007; 297:2705–15.
- 4 Sankila R, et al. Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries Association of the Nordic Cancer Registries and the Nordic Society of Pediatric Hematology and Oncology. *J Clin Oncol*. 1996; 14:1442–6. [PubMed: 8622057]
- 5 Armstrong GT, Stovall M, Robison LL. Long-term effects of radiation exposure among adult survivors of childhood cancer: results from the childhood cancer survivor study. *Radiat Res*. 2010; 174:840–50. [PubMed: 21128808]
- 6 Armstrong GT, Kawashima T, Leisenring W, Stratton K, Stovall M, Hudson MM, Sklar CA, Robison LL, Oeffinger KC. Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. *J Clin Oncol*. 2014; 32:1218–27. [PubMed: 24638000]
- 7 Meadows AT, Friedman DL, Neglia JP, Mertens AC, Donaldson SS, Stovall M, Hammond S, Yasui Y, Inskip PD. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. *J Clin Oncol*. 2009; 27:2356–62. [PubMed: 19255307]
- 8 Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF, Jr. *New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973–2000* Bethesda, MD: National Cancer Institute; 2006
- 9 Diller L, et al. Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings. *J Clin Oncol*. 2009; 27:2339–55. [PubMed: 19364955]
- 10 Inskip PD, Curtis RE. New malignancies following childhood cancer in the United States, 1973–2002. *Int J Cancer*. 2007; 121:2233–40. [PubMed: 17557301]
- 11 Guerin S, et al. Concomitant chemo-radiotherapy and local dose of radiation as risk factors for second malignant neoplasms after solid cancer in childhood: a case-control study. *Int J Cancer*. 2007; 120:96–102. [PubMed: 17013899]
- 12 Maule M, et al. Second malignancies after childhood noncentral nervous system solid cancer: Results from 13 cancer registries. *Int J Cancer*. 2011; 129:1940–52. [PubMed: 21520035]
- 13 Turcotte LM, et al. Temporal Trends in Treatment and Subsequent Neoplasm Risk Among 5-Year Survivors of Childhood Cancer, 1970–2015. *JAMA-J Am Med Assoc*. 2017; 317:814–24.
- 14 Armstrong GT, et al. Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer. *N Engl J Med*. 2016; 374:833–42. [PubMed: 26761625]
- 15 Salloum R, et al. Temporal trends in late-onset morbidity and mortality after medulloblastoma diagnosed across three decades: A report from the Childhood Cancer Survivor Study (CCSS). *J Clin Oncol*. 2017; 35:10516.
- 16 Armstrong GT, et al. Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. *J Natl Cancer Inst*. 2009; 101:946–58. [PubMed: 19535780]
- 17 American Cancer Society *Cancer Facts & Figures 2014* Atlanta: American Cancer Society; 2014

- 18 U.N. Department of Economic and Social Affairs World Population 2012 New York: United Nations; 2013
- 19 U.S. Central Intelligence Agency The World Factbook 2013–2014 Washington, DC: Central Intelligence Agency; 2013
- 20 Friedman DL, et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. *J Natl Cancer Inst.* 2010; 102:1083–95. [PubMed: 20634481]
- 21 Tsui K, et al. Subsequent neoplasms in survivors of childhood central nervous system tumors: risk after modern multimodal therapy. *Neuro Oncol.* 2015; 17:448–56. [PubMed: 25395462]
- 22 Strodbeck K, Sloan A, Rogers L, Fisher PG, Stearns D, Campbell L, Barnholtz-Sloan J. Risk of subsequent cancer following a primary CNS tumor. *J Neurooncol.* 2013; 112:285–95. [PubMed: 23392847]
- 23 Peterson KM, Shao C, McCarter R, MacDonald TJ, Byrne J. An analysis of SEER data of increasing risk of secondary malignant neoplasms among long-term survivors of childhood brain tumors. *Pediatr Blood Cancer.* 2006; 47:83–8. [PubMed: 16317732]
- 24 Goldstein AM, Yuen J, Tucker MA. Second cancers after medulloblastoma: population-based results from the United States and Sweden. *Cancer Cause Control.* 1997; 8:865–71.
- 25 Mulrooney DA, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. *Brit Med J.* 2009; 339:b4606. [PubMed: 19996459]
- 26 Chow EJ, et al. Individual prediction of heart failure among childhood cancer survivors. *J Clin Oncol.* 2015; 33:394–402. [PubMed: 25287823]
- 27 Christopherson KM, et al. Late toxicity following craniospinal radiation for early-stage medulloblastoma. *Acta Oncol.* 2014; 53:471–80. [PubMed: 24564687]
- 28 Grewal S, Merchant T, Reymond R, McInerney M, Hodge C, Shearer P. Auditory late effects of childhood cancer therapy: a report from the Children’s Oncology Group. *Pediatrics.* 2010; 125:e938–50. [PubMed: 20194279]
- 29 Huang E, et al. Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. *Int J Radiat Oncol Biol Phys.* 2002; 52:599–605. [PubMed: 11849779]
- 30 Gerosa MA, di Stefano E, Olivi A, Carteri A. Multidisciplinary treatment of medulloblastoma: a 5-year experience with the SIOP trial. *Child Brain.* 1981; 8:107–18.
- 31 Moxon-Emre I, et al. Impact of craniospinal dose, boost volume, and neurologic complications on intellectual outcome in patients with medulloblastoma. *J Clin Oncol.* 2014; 32:1760–8. [PubMed: 24516024]
- 32 Ris MD, Packer R, Goldwein J, Jones-Wallace D, Boyett JM. Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children’s Cancer Group study. *J Clin Oncol.* 2001; 19:3470–6. [PubMed: 11481352]
- 33 Silber JH, Radcliffe J, Peckham V, Perilongo G, Kishnani P, Fridman M, Goldwein JW, Meadows AT. Whole-brain irradiation and decline in intelligence: the influence of dose and age on IQ score. *J Clin Oncol.* 1992; 10:1390–6. [PubMed: 1517781]
- 34 Merchant TE, Hua CH, Shukla H, Ying X, Nill S, Oelfke U. Proton versus photon radiotherapy for common pediatric brain tumors: comparison of models of dose characteristics and their relationship to cognitive function. *Pediatr Blood Cancer.* 2008; 51:110–7. [PubMed: 18306274]
- 35 Balachandar S, Dunkel IJ, Khakoo Y, Wolden S, Allen J, Sklar CA. Ovarian function in survivors of childhood medulloblastoma: Impact of reduced dose craniospinal irradiation and high-dose chemotherapy with autologous stem cell rescue. *Pediatr Blood Cancer.* 2015; 62:317–21. [PubMed: 25346052]
- 36 Brown IH, Lee TJ, Eden OB, Bullimore JA, Savage DC. Growth and endocrine function after treatment for medulloblastoma. *Arch Dis Child.* 1983; 58:722–7. [PubMed: 6414386]
- 37 Livesey EA, Brook CG. Gonadal dysfunction after treatment of intracranial tumours. *Arch Dis Child.* 1988; 63:495–500. [PubMed: 3389863]
- 38 Wallace WH, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: who is at risk and what can be offered? *Lancet Oncol.* 2005; 6:209–18. [PubMed: 15811616]

- 39Huang TT, et al. Pulmonary outcomes in survivors of childhood central nervous system malignancies: a report from the Childhood Cancer Survivor Study. *Pediatr Blood Cancer*. 2014; 61:319–25. [PubMed: 24127436]
- 40Gurney JG, et al. Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study. *Cancer*. 2003; 97:663–73. [PubMed: 12548609]
- 41Oberfield SE, Allen JC, Pollack J, New MI, Levine LS. Long-term endocrine sequelae after treatment of medulloblastoma: prospective study of growth and thyroid function. *J Pediatr*. 1986; 108:219–23. [PubMed: 3944706]
- 42Pasqualini T, et al. Long-term endocrine sequelae after surgery, radiotherapy, and chemotherapy in children with medulloblastoma. *Cancer*. 1987; 59:801–6. [PubMed: 3802038]
- 43Xu W, Janss A, Packer RJ, Phillips P, Goldwein J, Moshang T Jr. Endocrine outcome in children with medulloblastoma treated with 18 Gy of craniospinal radiation therapy. *Neuro Oncol*. 2004; 6:113–8. [PubMed: 15134625]
- 44Childhood Cancer Survivor Study. CCSS Second Neoplasm Data Accessed 2015; Available from: <https://ccsstjudeorg/data-and-analysis/second-neoplasm-data.html>
- 45Kamal M, El-Khateeb N, Awad M, Zaghoul MS, Ahmed S, El-Beltagy M, Taha H, Refaat A, Abouelnaga S. Risk adapted treatment for medulloblastoma in children older than 3 years: Children's Cancer Hospital Egypt (CCHE) 57357 experience. *Neuro Oncol*. 2012; 14:i106.
- 46Bekelman JE, Schultheiss T, Berrington De Gonzalez A. Subsequent malignancies after photon versus proton radiation therapy. *Int J Radiat Oncol Biol Phys*. 2013; 87:10–2. [PubMed: 23810521]
- 47Pérez-Andújar A, Newhauser WD, Taddei PJ, Mahajan A, Howell RM. The predicted relative risk of premature ovarian failure for three radiotherapy modalities in a girl receiving craniospinal irradiation. *Phys Med Biol*. 2013; 58:3107–23. [PubMed: 23603657]
- 48Zhang R, Howell RM, Homann K, Giebeler A, Taddei PJ, Mahajan A, Newhauser WD. Predicted risks of radiogenic cardiac toxicity in two pediatric patients undergoing photon or proton radiotherapy. *Radiat Oncol*. 2013; 8:184. [PubMed: 23880421]
- 49Brodin NP, Munck Af Rosenschold P, Aznar MC, Kiil-Berthelsen A, Vogelius IR, Nilsson P, Lannering B, Bjork-Eriksson T. Radiobiological risk estimates of adverse events and secondary cancer for proton and photon radiation therapy of pediatric medulloblastoma. *Acta Oncol*. 2011; 50:806–16. [PubMed: 21767178]
- 50Newhauser WD, et al. The risk of developing a second cancer after receiving craniospinal proton irradiation. *Phys Med Biol*. 2009; 54:2277–91. [PubMed: 19305036]
- 51Zhang R, Howell RM, Taddei PJ, Giebeler A, Mahajan A, Newhauser WD. A comparative study on the risks of radiogenic second cancers and cardiac mortality in a set of pediatric medulloblastoma patients treated with photon or proton craniospinal irradiation. *Radiother Oncol*. 2014; 113:84–8. [PubMed: 25128084]
- 52Taddei PJ, Khater N, Zhang R, Geara FB, Mahajan A, Jalbout W, Pérez-Andújar A, Youssef B, Newhauser WD. Inter-Institutional Comparison of Personalized Risk Assessments for Second Malignant Neoplasms for a 13-Year-Old Girl Receiving Proton versus Photon Craniospinal Irradiation. *Cancers*. 2015; 7:407–26. [PubMed: 25763928]
- 53Miralbell R, Lomax A, Cella L, Schneider U. Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. *Int J Radiat Oncol Biol Phys*. 2002; 54:824–9. [PubMed: 12377335]
- 54Mu X, Bjork-Eriksson T, Nill S, Oelfke U, Johansson KA, Gagliardi G, Johansson L, Karlsson M, Zackrisson DB. Does electron and proton therapy reduce the risk of radiation induced cancer after spinal irradiation for childhood medulloblastoma? A comparative treatment planning study. *Acta Oncol*. 2005; 44:554–62. [PubMed: 16165914]
- 55International Atomic Energy Agency. Directory of RAdiotherapy Centres Accessed October 2014 Available from: <http://www-nawebiaeaorg/nahu/dirac/query.asp>
- 56Group Particle Therapy Co-Operative. Particle Therapy Co-Operative Group - Facilities in Operation website Accessed August 2015; Available from: <http://www.ptcogch/indexphp/facilities-in-operation>

- 57Giebler A, Newhauser WD, Amos RA, Mahajan A, Homann K, Howell RM. Standardized treatment planning methodology for passively scattered proton craniospinal irradiation. *Radiat Oncol.* 2013; 8:32. [PubMed: 23375151]
- 58Newhauser W, Jones T, Swerdloff S, Newhauser W, Cilia M, Carver R, Halloran A, Zhang R. Anonymization of DICOM electronic medical records for radiation therapy. *Comput Biol Med.* 2014; 53:134–40. [PubMed: 25147130]
- 59US News & World Report. U S News Best Hospitals: Cancer website Accessed 2015; Available from: <http://healthusnewscom/best-hospitals/rankings/cancer>
- 60World Bank Group. Country and Lending Groups Data website Accessed 2014; Available from: <http://dataworldbankorg/about/country-classifications/country-and-lending-groups>
- 61Lunsford TR, Lunsford BR. The Research Sample, Part I: Sampling. *J Prosthet Orthot.* 1995; 7:105–12.
- 62Cristy M. Active bone marrow distribution as a function of age in humans. *Phys Med Biol.* 1981; 26:389–400. [PubMed: 7243876]
- 63Howell RM, Giebler A, Koontz-Raisig W, Mahajan A, Etzel CJ, D'Amelio AM Jr, Homann KL, Newhauser WD. Comparison of therapeutic dosimetric data from passively scattered proton and photon craniospinal irradiations for medulloblastoma. *Radiat Oncol.* 2012; 7:116. [PubMed: 22828073]
- 64International Commission on Radiation Units and Measurements *Journal of the ICRU Oxford: International Commission on Radiation Units and Measurements, Inc; 2007 ICRU REPORT 78: Prescribing, Recording, and Reporting Proton-Beam Therapy.*
- 65Taddei PJ, Mahajan A, Mirkovic D, Zhang R, Giebler A, Kornguth D, Harvey M, Woo S, Newhauser WD. Predicted risks of second malignant neoplasm incidence and mortality due to secondary neutrons in a girl and boy receiving proton craniospinal irradiation. *Phys Med Biol.* 2010; 55:7067–80. [PubMed: 21076189]
- 66International Commission on Radiation Units and Measurements *ICRU Report 49: Stopping Powers and Ranges for Protons and Alpha Particles Bethesda, MD: International Commission on Radiation Units and Measurements, Inc; 1993*
- 67Robertson JB, Eaddy JM, Archambeau JO, Coutrakon GB, Miller DW, Moyers MF, Siebers JV, Slater JM, Dicello JF. Variation in measured proton relative biological effectiveness as a function of initial proton energy. In: Amaldi U, Larsson B, editors *Hadrontherapy in Oncology Amsterdam: Excerpta Medica; 1994*
- 68ICRP *Ann ICRP New York: Pergamon Press; 1991 Recommendations of the International Commission on Radiological Protection: Publication 60.*
- 69Taddei PJ, Borak TB, Guetersloh SB, Gersey BB, Zeitlin C, Heilbronn L, Miller J, Murakami T, Iwata Y. The response of a spherical tissue-equivalent proportional counter to different heavy ions having similar velocities. *Radiat Meas.* 2006; 4179:1227–34. [PubMed: 19079798]
- 70Borak TB, et al. Comparisons of LET distributions for protons with energies between 50 and 200 MeV determined using a spherical tissue-equivalent proportional counter (TEPC) and a position-sensitive silicon spectrometer (RRMD-III). *Radiat Res.* 2004; 162:687–92. [PubMed: 15548122]
- 71Tung CJ. Microdosimetric relative biological effectiveness of therapeutic proton beams. *Biomed J.* 2015; 38:399–407. [PubMed: 26459792]
- 72Coutrakon G, Cortese J, Ghebremedhin A, Hubbard J, Johanning J, Koss P, Maudsley G, Slater CR, Zuccarelli C. Microdosimetry spectra of the Loma Linda proton beam and relative biological effectiveness comparisons. *Med Phys.* 1997; 24:1499–506. [PubMed: 9304579]
- 73Howell RM, Scarboro SB, Taddei PJ, Krishnan S, Kry SF, Newhauser WD. Methodology for determining doses to in-field, out-of-field and partially in-field organs for late effects studies in photon radiotherapy. *Phys Med Biol.* 2010; 55:7009–23. [PubMed: 21076193]
- 74Huang JY, Followill DS, Wang XA, Kry SF. Accuracy and sources of error of out-of field dose calculations by a commercial treatment planning system for intensity-modulated radiation therapy treatments. *J Appl Clin Med Phys.* 2013; 14:186.
- 75Taddei PJ, Jalbout W, Howell RM, Khater N, Geara F, Homann K, Newhauser WD. Analytical model for out-of-field dose in photon craniospinal irradiation. *Phys Med Biol.* 2013; 58:7463–79. [PubMed: 24099782]

- 76Zhang R, Fontenot JD, Mirkovic D, Hendricks JS, Newhauser WD. Advantages of MCNPX-based lattice tally over mesh tally in high-speed Monte Carlo dose reconstruction for proton radiotherapy. *Nucl Technol.* 2013; 183:101–6. [PubMed: 25435594]
- 77NRCNAHealth Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII -Phase 2 Washington, DC: The National Academies Press; 2006
- 78Preston DL, Pierce DA, Shimizu Y, Cullings HM, Fujita S, Funamoto S, Kodama K. Effect of recent changes in atomic bomb survivor dosimetry on cancer mortality risk estimates. *Radiat Res.* 2004; 162:377–89. [PubMed: 15447045]
- 79Little MP. Leukaemia following childhood radiation exposure in the Japanese atomic bomb survivors and in medically exposed groups. *Radiat Prot Dosim.* 2008; 132:156–65.
- 80Shuryak I, Sachs RK, Hlatky L, Little MP, Hahnfeldt P, Brenner DJ. Radiation-induced leukemia at doses relevant to radiation therapy: modeling mechanisms and estimating risks. *J Natl Cancer Inst.* 2006; 98:1794–806. [PubMed: 17179481]
- 81Berrington de Gonzalez A, Iulian Apostoaei A, Veiga LH, Rajaraman P, Thomas BA, Owen Hoffman F, Gilbert E, Land C. RadRAT: a radiation risk assessment tool for lifetime cancer risk projection. *J Radiol Prot.* 2012; 32:205–22. [PubMed: 22810503]
- 82Sachs RK, Brenner DJ. Solid tumor risks after high doses of ionizing radiation. *Proc Natl Acad Sci U S A.* 2005; 102:13040–5. [PubMed: 16150705]
- 83Sigurdson AJ, et al. Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study. *Lancet.* 2005; 365:2014–23. [PubMed: 15950715]
- 84Fontenot JD, Bloch C, Followill D, Titt U, Newhauser WD. Estimate of the uncertainties in the relative risk of secondary malignant neoplasms following proton therapy and intensity-modulated photon therapy. *Phys Med Biol.* 2010; 55:6987–98. [PubMed: 21076196]
- 85Kry SF, Followill D, White RA, Stovall M, Kuban DA, Salehpour M. Uncertainty of calculated risk estimates for secondary malignancies after radiotherapy. *Int J Radiat Oncol Biol Phys.* 2007; 68:1265–71. [PubMed: 17637398]
- 86Nguyen J, Moteabbed M, Paganetti H. Assessment of uncertainties in radiation-induced cancer risk predictions at clinically relevant doses. *Med Phys.* 2015; 42:81–9. [PubMed: 25563249]
- 87Zhang R. Quantitative comparison of late effects following photon versus proton external-beam radiation therapies: Toward an evidence-based approach to selecting a treatment modality (Dissertation) Houston, TX: The University of Texas Graduate School of Biomedical Sciences at Houston; 2008
- 88Stokkevag CH, et al. Estimated risk of radiation-induced cancer following paediatric cranio-spinal irradiation with electron, photon and proton therapy. *Acta Oncol.* 2014; 53:1048–57. [PubMed: 25017376]
- 89Packer RJ, Zhou T, Holmes E, Vezina G, Gajjar A. Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961. *Neuro Oncol.* 2013; 15:97–103. [PubMed: 23099653]
- 90Sabin ND, et al. Incidental detection of late subsequent intracranial neoplasms with magnetic resonance imaging among adult survivors of childhood cancer. *J Cancer Surviv.* 2014; 8:329–35. [PubMed: 24488818]
- 91Banerjee J, Pääkkö E, Harila M, Herva R, Tuominen J, Koivula A, Lanning M, Harila-Saari A. Radiation-induced meningiomas: A shadow in the success story of childhood leukemia. *Neuro Oncol.* 2009; 11:543–9. [PubMed: 19179425]
- 92Green DM, Zevon MA, Reese PA, Lowrie GS, Gaeta JF, Pearce JI, Michalek AM, Stephens EA. Second malignant tumors following treatment during childhood and adolescence for cancer. *Med Pediatr Oncol.* 1994; 22:1–10. [PubMed: 8232073]
- 93de Vathaire F, , Scwhartz B, , El-Fayech C, , Allodji RS, , Escudier B, , Hawkins M, , Diallo I, , Haddy N. Risk of a Second Kidney Carcinoma Following Childhood Cancer: Role of Chemotherapy and of Radiation Dose to Kidneys. *J Urol.* 194(2015):1390–5. [PubMed: 26143112]
- 94Turcotte LM, Whitton JA, Friedman DL, Hammond S, Armstrong GT, Leisenring W, Robison LL, Neglia JP. Risk of Subsequent Neoplasms During the Fifth and Sixth Decades of Life in the Childhood Cancer Survivor Study Cohort. *J Clin Oncol.* 2015

- 95Olsen JH, et al. Lifelong cancer incidence in 47, 697 patients treated for childhood cancer in the Nordic countries. *J Natl Cancer Inst.* 2009; 101:806–13. [PubMed: 19470947]
- 96Taddei PJ, Mirkovic D, Fontenot JD, Giebeler A, Zheng Y, Kornguth D, Mohan R, Newhauser WD. Stray radiation dose and second cancer risk for a pediatric patient receiving craniospinal irradiation with proton beams. *Phys Med Biol.* 2009; 54:2259–75. [PubMed: 19305045]
- 97Zhang R, Howell RM, Giebeler A, Taddei PJ, Mahajan A, Newhauser WD. Comparison of risk of radiogenic second cancer following photon and proton craniospinal irradiation for a pediatric medulloblastoma patient. *Phys Med Biol.* 2013; 58:807–23. [PubMed: 23322160]
- 98Newhauser WD, et al. Contemporary Proton Therapy Systems Adequately Protect Patients from Exposure to Stray Radiation. *AIP Conf Proc.* 2009; 1099:450–5. [PubMed: 20844607]
- 99Yock TI, Caruso PA. Risk of second cancers after photon and proton radiotherapy: a review of the data. *Health Phys.* 2012; 103:577–85. [PubMed: 23032887]
- 100Mahajan A. DOTmed Daily News New York: DOTmedcom, Inc; 2013 Why is IMPT a smart treatment option for pediatric patients?.
- 101Taddei PJ, Mirkovic D, Fontenot JD, Giebeler A, Zheng Y, Titt U, Woo S, Newhauser WD. Reducing stray radiation dose for a pediatric patient receiving proton craniospinal irradiation. *Nucl Technol.* 2009; 168:108–12. [PubMed: 20865143]
- 102Ferlay J, , et al. GLOBOCAN 2012 v10, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No 11 Lyon, France: International Agency for Research on Cancer; 2013
- 103Packer RJ, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. *J Clin Oncol.* 2006; 24:4202–8. [PubMed: 16943538]
- 104Daher M. Cancer Strategy in Lebanon Clemenceau Medical Center; Beirut, Lebanon: 2015 10/30/2015
- 105AUBMC. Annual Report. 2013
- 106Pelletier J. ProNova Solutions, LLC 2015 Apr. personal communication2015
- 107World Health OrganizationRadiotherapy Systems ECRI Institute; 2011
- 108Mailhot Vega RB, , Kim J, , Bussiere M, , Hattangadi J, , Hollander A, , Michalski J, , Tarbell NJ, , Yock T, , MacDonald SM. Cost effectiveness of proton therapy compared with photon therapy in the management of pediatric medulloblastoma. *Cancer.* 2013; 119:4299–307. [PubMed: 24105630]
- 109Adib S. Latest Epidemiology Trends of Cancer in Lebanon Clemenceau Medical Center; Beirut, Lebanon: 2015 10/30/2015
- 110U.S. Environmental Protection AgencyRadiogenic Cancer Risk Models and Projections for the US Population Washington, DC: U.S. Environmental Protection Agency; 2011 Report No EPA 402-R-11-001
- 111Berrington de Gonzalez A, Gilbert E, Curtis R, Inskip P, Kleinerman R, Morton L, Rajaraman P, Little MP. Second Solid Cancers After Radiation Therapy: A Systematic Review of the Epidemiologic Studies of the Radiation Dose-Response Relationship. *Int J Radiat Oncol Biol Phys.* 2013; 86:224–33. [PubMed: 23102695]
- 112Kovalchik SA, et al. Absolute risk prediction of second primary thyroid cancer among 5-year survivors of childhood cancer. *J Clin Oncol.* 2013; 31:119–27. [PubMed: 23169509]
- 113Müller AC, Ganswindt U, Bamberg M, Belka C. Risk of second malignancies after prostate irradiation? *Strahlenther Onkol.* 2007; 183:605–9. [PubMed: 17960335]
- 114Schulz RJ. Proton-beam therapy: are physicists ignoring clinical realities? *J Appl Clin Med Phys.* 2015; 16:5710. [PubMed: 26103506]





Figure 1.
 LAR of leukemia incidence for 5-year old boys (solid line) and a 5-year-old girls (dashed line) calculated by our model as a function of the mean equivalent dose in the red bone marrow.

a.



b.




Figure 2. Mean LAR values of SMN incidence (top panel) and mortality (bottom panel), averaged across all patients for photon CSI and proton CSI. One-sided error bars represent the 95% confidence interval in each mean value for a particular SMN and do not take into account the large uncertainties in the risk model.




Figure 3.

Mean ratios of LAR values from proton CSI to those of photon CSI averaged across all patients for each known radiogenic SMN site. The error bars show the spread between maximum and minimum values for all nine patients.

Patient characteristics and absolute risk coefficients for L_{AR} of SMN incidence, I_T , and L_{AR} of SMN mortality, M_T . The coefficients are listed in percent risk per 0.1 Sv of equivalent dose.

Table 1

Age at exposure (y):	2	3	6	8	9	13	13
Sex:	Female	Male	Female	Male	Female	Male	Female
Mass in TPS (kg):	9.2	8.9	16.2	20.5	20.7	16.1	30.9
Actual mass (kg):	11.9	12.8	24.9	26.9	29.0	24.2	42.6
Fraction of mass in TPS:	0.78	0.70	0.65	0.76	0.71	0.67	0.73
Patient Index:	1	2	3	4	5	6	7
	8	9					
SMN site	I_T (%)						
Bladder	0.199	0.190	0.172	0.174	0.163	0.158	0.138
Leukemia	0.156	0.184	0.143	0.107	0.096	0.091	0.126
Breast	1.068	—	—	0.874	0.793	0.752	—
Liver	0.026	0.054	0.049	0.022	0.021	0.021	0.044
Lung	0.683	0.282	0.252	0.587	0.546	0.525	0.452
Ovarian	0.097	—	—	0.084	0.079	0.076	—
Prostate	—	0.085	0.077	—	—	—	0.070
Other solid tumors	1.091	0.852	0.638	0.680	0.601	0.562	0.455
NMSC	1.639	0.779	0.645	1.258	1.138	1.078	0.889
Stomach	0.095	0.069	0.063	0.082	0.077	0.075	0.065
Thyroid	0.548	0.092	0.071	0.390	0.333	0.304	0.055
Uterine	0.047	—	—	0.041	0.038	0.037	—
Colon	0.207	0.305	0.276	0.181	0.170	0.164	0.250
							0.144
SMN site	M_T (%)						
Bladder	0.056	0.041	0.037	0.049	0.046	0.045	0.033
Leukemia	0.053	0.071	0.071	0.052	0.053	0.053	0.071
Breast	0.250	—	—	0.205	0.186	0.176	—
Liver	0.022	0.040	0.036	0.019	0.018	0.018	0.032
Lung	0.599	0.286	0.255	0.516	0.479	0.460	0.228
Ovarian	0.052	—	—	0.045	0.042	0.041	—
							0.036

Age at exposure (y):	2	3	6	6	8	9	9	13	13
Sex:	Female	Male	Male	Female	Female	Female	Male	Female	Male
Mass in TPS (kg):	9.2	8.9	16.2	20.5	20.7	16.1	21.5	30.9	31.7
Actual mass (kg):	11.9	12.8	24.9	26.9	29.0	24.2	29.6	42.6	57.5
Fraction of mass in TPS:	0.78	0.70	0.65	0.76	0.71	0.67	0.73	0.73	0.55
Patient Index:	1	2	3	4	5	6	7	8	9
Prostate	—	0.016	0.014	—	—	—	0.013	—	0.011
Other solid tumors	0.409	0.313	0.244	0.274	0.247	0.233	0.211	0.195	0.177
NMSC	0.003	0.002	0.001	0.002	0.002	0.002	0.001	0.002	0.001
Stomach	0.053	0.037	0.033	0.047	0.044	0.042	0.031	0.037	0.027
Thyroid	0.055	0.009	0.007	0.039	0.033	0.030	0.006	0.022	0.004
Uterine	0.011	—	—	0.010	0.009	0.008	—	0.007	—
Colon	0.096	0.149	0.135	0.083	0.078	0.076	0.121	0.066	0.106

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Mean equivalent doses in organs and tissues, H_T ; and in the whole body in photon CSI or proton CSI, expressed in Sv for a 23.4-Gy CSI treatment. The standard deviations of the means in this table were for the variability between patients, not for statistical uncertainty by error propagation.

Table 2

Age at exposure (y):	2	3	6	6	8	8	9	9	9	13	13	
Sex:	F	M	M	F	F	F	F	M	M	F	M	
Patient Index:	1	2	3	4	5	6	7	8	9	8	9	
Photon CSI												
Organ or tissue	Average											Standard deviation
Whole body	7.476	7.269	4.774	4.585	4.540	5.187	4.955	3.989	3.565	5.149	1.352	
Bladder	2.536	7.103	1.892	1.449	1.388	1.276	1.118	1.065	1.215	2.116	1.927	
Red bone marrow	5.874	4.922	6.161	6.378	6.712	4.555	6.156	7.233	4.598	5.843	0.951	
Breast tissue	5.450	—	—	1.798	1.658	1.790	—	1.068	—	2.353	1.757	
Liver	7.640	5.285	4.211	5.318	3.912	4.547	4.688	4.193	4.054	4.872	1.154	
Lungs	9.455	3.917	2.816	3.549	2.754	2.980	3.304	2.953	2.120	3.761	2.195	
Ovaries	2.291	—	—	1.192	2.565	1.360	—	1.203	—	1.722	0.655	
Prostate	—	0.992	0.825	—	—	—	0.856	—	1.041	0.928	0.105	
Remainder	7.964	8.598	5.381	4.974	5.001	6.084	5.511	4.259	4.042	5.757	1.566	
Skin	4.014	3.797	2.334	2.255	2.187	2.701	2.527	2.566	1.605	2.665	0.771	
Stomach	14.338	3.078	2.202	2.066	3.144	4.785	1.949	5.726	2.469	4.417	3.937	
Thyroid	18.885	18.418	17.999	16.251	16.181	16.058	17.791	16.447	15.789	17.091	1.173	
Uterus	1.951	—	—	1.207	1.921	1.331	—	1.077	—	1.497	0.410	
Colon	11.166	6.282	5.086	5.207	5.880	4.616	4.945	5.783	3.398	5.818	2.173	
Proton CSI												
Organ or tissue	Average											Standard deviation
Whole body	5.205	6.074	4.246	3.692	3.800	4.281	3.059	2.731	2.447	3.948	1.168	
Bladder	0.134	0.391	0.178	0.143	0.077	0.140	0.131	0.130	0.043	0.152	0.098	
Red bone marrow	5.020	4.465	5.427	5.102	6.155	4.251	4.062	6.384	3.110	4.886	1.038	
Breast tissue	0.237	—	—	0.219	0.203	0.270	—	0.267	—	0.239	0.029	
Liver	0.451	0.544	0.509	0.407	0.611	0.527	0.299	0.713	0.218	0.475	0.153	
Lungs	3.440	3.876	2.675	3.558	1.875	3.161	1.441	2.242	1.415	2.631	0.933	

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

	Age at exposure (y):		6		9		13		13		
	2	3	6	6	9	9	13	13	13	13	
Sex:	F	M	F	M	F	M	F	M	F	M	
Patient Index:	1	2	3	4	5	6	7	8	9	9	
Ovaries	0.198	—	—	0.193	0.170	0.221	—	0.256	—	0.208	0.032
Prostate	—	0.131	0.138	—	—	—	0.123	—	0.010	0.101	0.061
Remainder	5.933	7.473	4.864	4.142	4.408	5.239	3.519	2.984	2.879	4.605	1.479
Skin	4.166	4.322	3.300	2.931	3.137	3.200	2.428	2.609	2.006	3.122	0.758
Stomach	0.237	0.552	0.856	0.529	0.461	0.325	0.283	0.342	0.196	0.420	0.206
Thyroid	0.792	0.727	0.769	0.488	0.499	0.547	0.763	0.841	0.529	0.662	0.142
Uterus	0.229	—	—	0.198	0.106	0.220	—	0.239	—	0.199	0.054
Colon	0.491	0.380	0.568	0.301	0.489	0.422	0.750	0.366	0.183	0.439	0.163

Mean equivalent doses in organs and tissues, H_T ; and in the whole body from external or internal neutrons in proton CSI, expressed in Sv. The standard deviations of the means in this table were for the variability between patients, not for statistical uncertainty by error propagation.

Table 3

Age at exposure (y):	2	3	6	6	8	8	9	9	13	13		
Sex:	F	M	M	F	F	F	F	M	F	M		
Patient Index:	1	2	3	4	5	6	7	8	9	9		
External neutrons from proton CSI												
Organ or tissue											Average	Standard deviation
Whole body	0.115	0.114	0.118	0.122	0.116	0.137	0.133	0.181	0.094	0.126	0.024	
Bladder	0.099	0.116	0.118	0.102	0.058	0.110	0.104	0.086	0.031	0.092	0.029	
Red bone marrow	0.095	0.093	0.095	0.099	0.102	0.107	0.106	0.148	0.074	0.102	0.020	
Breast tissue	0.150	—	—	0.151	0.148	0.186	—	0.214	—	0.170	0.029	
Liver	0.139	0.149	0.176	0.153	0.183	0.192	0.169	0.255	0.139	0.173	0.036	
Lungs	0.167	0.186	0.211	0.200	0.208	0.242	0.232	0.322	0.205	0.219	0.044	
Ovaries	0.114	—	—	0.118	0.122	0.143	—	0.160	—	0.131	0.020	
Prostate	—	0.107	0.107	—	—	—	0.103	—	0.008	0.081	0.049	
Remainder	0.116	0.116	0.118	0.122	0.115	0.139	0.133	0.182	0.095	0.126	0.024	
Skin	0.116	0.111	0.120	0.124	0.124	0.141	0.131	0.184	0.091	0.127	0.026	
Stomach	0.150	0.145	0.187	0.165	0.155	0.179	0.175	0.226	0.143	0.169	0.026	
Thyroid	0.179	0.183	0.192	0.184	0.187	0.211	0.224	0.293	0.216	0.208	0.036	
Uterus	0.111	—	—	0.118	0.077	0.144	—	0.148	—	0.119	0.029	
Colon	0.123	0.116	0.152	0.135	0.147	0.156	0.146	0.185	0.112	0.141	0.023	
Internal neutrons from proton CSI												
Organ or tissue											Average	Standard deviation
Whole body	0.156	0.183	0.140	0.120	0.120	0.145	0.115	0.101	0.084	0.129	0.030	
Bladder	0.032	0.031	0.049	0.036	0.017	0.029	0.027	0.042	0.010	0.030	0.012	
Red bone marrow	0.105	0.103	0.117	0.100	0.132	0.111	0.103	0.161	0.072	0.112	0.024	
Breast tissue	0.074	—	—	0.060	0.053	0.069	—	0.050	—	0.061	0.010	
Liver	0.060	0.052	0.086	0.065	0.072	0.080	0.056	0.087	0.053	0.068	0.014	
Lungs	0.109	0.099	0.121	0.107	0.097	0.128	0.089	0.118	0.086	0.106	0.015	

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Age at exposure (y):	2	3	6	6	6	8	9	9	9	13	13	
Sex:	F	M	M	F	F	F	F	M	M	F	M	
Patient Index:	1	2	3	4	5	6	7	8	9	8	9	
Ovaries	0.043	—	—	0.038	0.048	0.048	0.045	—	0.063	—	0.048	0.010
Prostate	—	0.013	0.027	—	—	—	—	0.019	—	0.000	0.015	0.011
Remainder	0.176	0.225	0.157	0.134	0.134	0.171	0.130	0.130	0.108	0.096	0.148	0.039
Skin	0.110	0.116	0.097	0.086	0.101	0.108	0.081	0.081	0.081	0.059	0.093	0.018
Stomach	0.079	0.053	0.101	0.067	0.067	0.077	0.059	0.059	0.095	0.052	0.072	0.017
Thyroid	0.226	0.226	0.255	0.208	0.210	0.229	0.241	0.241	0.208	0.154	0.218	0.029
Uterus	0.041	—	—	0.039	0.028	0.046	—	0.055	—	—	0.042	0.010
Colon	0.053	0.033	0.089	0.064	0.078	0.063	0.054	0.054	0.081	0.050	0.063	0.018